Sanofi, GSK sign deal to supply 300 million doses of Covid-19 vaccine in EU states

This article was originally published here

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

The post Sanofi, GSK sign deal to supply 300 million doses of Covid-19 vaccine in EU states appeared first on Pharmaceutical Business review.